TY - JOUR
TI - Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients' survival
AU - Giaginis, C.
AU - Damaskos, C.
AU - Koutsounas, I.
AU - Zizi-Serbetzoglou, A.
AU - Tsoukalas, N.
AU - Patsouris, E.
AU - Kouraklis, G.
AU - Theocharis, S.
JO - BMC Gastroenterology
PY - 2015
VL - 15
TODO - 1
SP - null
PB - BioMed Central Ltd.
SN - 1471-230X
TODO - 10.1186/s12876-015-0379-y
TODO - histone deacetylase 1;  histone deacetylase 2;  histone deacetylase 4;  histone deacetylase 6;  HDAC1 protein, human;  HDAC2 protein, human;  HDAC4 protein, human;  HDAC6 protein, human;  histone deacetylase;  histone deacetylase 1;  histone deacetylase 2;  repressor protein;  tumor marker, adult;  aged;  Article;  cancer growth;  cancer prognosis;  cancer staging;  cancer survival;  clinical article;  controlled study;  disease association;  enzyme localization;  female;  human;  human tissue;  immunoreactivity;  male;  overall survival;  pancreas adenocarcinoma;  protein expression;  survival time;  tumor volume;  adenocarcinoma;  cell proliferation;  enzymology;  gene expression;  genetics;  metabolism;  metastasis;  middle aged;  mortality;  pancreas tumor;  pathology, Adenocarcinoma;  Aged;  Biomarkers, Tumor;  Cell Proliferation;  Female;  Gene Expression;  Histone Deacetylase 1;  Histone Deacetylase 2;  Histone Deacetylases;  Humans;  Male;  Middle Aged;  Neoplasm Metastasis;  Pancreatic Neoplasms;  Repressor Proteins
TODO - Background: Histone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, -2, -4 and -6 protein expression in pancreatic adenocarcinoma. Methods: HDAC-1, -2, -4 and -6 protein expression was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was statistically analyzed with clinicopathological characteristics and patients' survival. Results: Enhanced HDAC-1 expression was significantly associated with increased tumor proliferative capacity (p = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632). Elevated HDAC-4 expression was significantly associated with the absence of organ metastases (p = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferative capacity (p = 0.0576). Enhanced HDAC-6 expression was significantly associated with earlier histopathological stage (p = 0.0115) and borderline with smaller tumor size (p = 0.0864). Pancreatic adenocarcinoma patients with enhanced HDAC-1 and -6 expression showed significantly longer survival times compared to those with low expression (p = 0.0022 and p = 0.0113, respectively), while a borderline association concerning HDAC-2 expression was noted (p = 0.0634). Conclusions: The present study suggested that HDACs may be implicated in pancreatic malignant disease progression, being considered of clinical utility with potential use as therapeutic targets. © 2015 Giaginis et al.
ER -